Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.
Real-world tracking identified uncommon side effects of the popular weight-loss drug tirzepatide occurring mainly in the first month, guiding safer patient monitoring.
This large pharmacovigilance study of 123,145 FAERS reports characterizes tirzepatide's post-approval safety signal landscape across three years of real-world use in diabetes and obesity treatment, identifying novel unlabeled adverse events (starvation ketoacidosis, food cravings) not prominent in pivotal trials and showing that most adverse events cluster in the first 30 days of treatment. The differential safety profile versus semaglutide (lower vomiting/constipation odds) provides clinically actionable guidance for drug selection and patient monitoring in clinical practice.
What the study was
- Study design
- Retrospective pharmacovigilance study (FAERS database Q2 2022–Q4 2025)
- Population
- FAERS real-world adverse event reports with tirzepatide as primary suspected drug (n=123,145 reports)
- Sample size
- 123145
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Diabetes, obesity & metabolism
Why it surfaced
Large real-world pharmacovigilance study of the widely adopted tirzepatide identifies novel unlabeled safety signals and informs clinical monitoring protocols; starvation ketoacidosis signal is potentially serious and warrants early recognition guidance for prescribers.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.